# Denosumab Strategy for Liver Cancer With Bone Metastases

> **NCT07537972** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tongji Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Bone Metastases

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Sintilimab
- **OTHER:** Delayed/Rescue Bone-Modifying Strategy

## Key facts

- **NCT ID:** NCT07537972
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-05-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07537972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07537972, "Denosumab Strategy for Liver Cancer With Bone Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07537972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*